🇪🇺EU · EMAAuthorisedATC: H02AB09

Alkindi(hydrocortisone)

Adrenal Insufficiency

Marketing Authorisation Holder: Immedica Netherlands B.V.

EMA Authorisation: 09/02/2018

INN: hydrocortisone

Indication

Replacement therapy of adrenal insufficiency in infants, children and adolescents (from birth to < 18 years old).

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Alkindi — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about Alkindi Create Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.